Several approaches for anticancer drug development progress

Abstract

Anticancer drug development is facing increasingly challenge. Much more chemicals or bio-agents are required to be evaluated every year. High-quality and speediness of drug evaluation requires joint-efforts between chemists and pharmacologists. This Editorial provides this area of anticancer drug discovery, development and licensing.

Anti-metastatic drug development, overview and perspectives

“…Anticancer drug development is entering into a bottleneck stage from a great expanding of tumor models and sophisticate technology. [12][13][14][83][84][85][86] Due to these cutting-edge technology, the research and evaluative fund is boosting than ever before. Therefore, repeat work should be avoided.…”